Fresenius Medical Launches 4008A Dialysis Machine In China
Zacks Investment Research | Sep 19, 2019 10:57PM ET
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) recently launched its 4008A dialysis machine to treat patients in China, who are suffering from the end-stage renal disease (ESRD). This latest move further fortifies the company’s foothold in the Asia Pacific dialysis care market.
Following the announcement, shares of this Zacks Rank #3 (Hold) company inched up 0.5% to $35.02 at close.
For investors’ notice, ESRD is the stage in kidney disease when a person's kidneys permanently stop working. The patient requires a long-term dialysis or a kidney transplant.
More on the News
Fresenius Medical’s 4008A dialysis machine is a major breakthrough and an outcome of the collaboration between the Fresenius Medical Care China Design Center in Shanghai and the company’s research and development teams in Germany.
The machine is specially designed to treat a vast number of patients and also ideal for use in remote locations.
Fresenius Medical also announced an initiative dedicated toward providing care and education to nephrologists, nursing staff and patients in areas with inadequate health care resources in China.
Strong Presence in APAC
In China, there are more than 600,000 patients with access to dialysis but the estimated ESRD prevalence is much higher. As part of the ‘Healthy China 2030’ initiative, the government of China has been making efforts to expand the reach of quality medical resources to rural areas in recent times.
It is encouraging to note that, earlier this year, Fresenius Medical launched the 4008A dialysis machine in India as well.
In the recent past, the leading dialysis provider widened its footprint in in the APAC region by acquiring large shares in multiple Chinese companies and hospital systems.
In fact, in the last reported quarter, Fresenius Medical saw strong organic growth in the APAC region.
Market Prospects
Baxter’s long-term earnings are expected to grow 12.8%.
CONMED’s long-term earnings are projected to increase 12.8%.
Masimo’s long-term earnings are estimated to rise 20.5%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.